Abstract
A staging hybrid F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in a 78-year-old man with bone metastases from non-small cell lung cancer (NSCLC) revealed markedly focal FDG uptake in multiple vertebrae, but without clearly visible bone metastases (a). After 4 months of oral treatment with erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor, EGFRTKI), follow-up PET/CT showed a remarkable decrease in FDG uptake in the otherwise now clearly sclerotic bone metastases (b). An osteoblastic healing response (OHR), defined as the induction of osteoblastic bone lesions and associated with
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
